Abstract
HEMOCO is a multicenter prospective cohort set up in 1989 to monitor 407 French hemophiliacs infected by HIV-1 and recruited in 4 hemophilia treatment centers in the Paris region. As of 15 July 1995, 42% of the patients in the cohort had developed stage B HIV disease and 29% stage C disease (AIDS); 23.1% of the patients had died. The cumulative proportion of patients with AIDS was 4.5% at 5 years and 27.4% at 10 years, while the respective mortality rates were 3.8% and 19.5%. In our study, only age was predictive of AIDS, with an estimated relative risk of 1.2 per 10-year age increment; this factor was also predictive of death. After 10 years of follow-up, 6.1% of the study population had no clinical or laboratory signs of immunodepression. The follow-up protocol in the HEMOCO protocol is the same as that in the French SEROCO study, which includes men infected by HIV-1 through sexual contact. This will allow us to compare the progression of HIV infection between these two exposure groups.
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Additional information
HEMOCO Study Group: Y Sultan, N Stieltjes: Centre des Hémophiles, Groupe Hospitalier Cochin, Paris; C Gazengel, C Rothschild, M F Torchet: Centre d’Hémobiologie Transfusion Paris Ouest, Hôpital Necker Enfants Malades, Paris; Y Laurian, A Blanc, R d’Oiron, A Rafowicz, L Kebedjis: Centre de Traitement de l’Hémophilie, Hôpital du Kremlin-Bicêtre, Le Kremlin-Bicêtre; J Peynet, C Laux: Centre de Transfusion des Yvelines, Centre de Traitement de l’Hémophilie, Centre Hospitalier de Versailles, Le Chesnay
Rights and permissions
About this article
Cite this article
Boufassa, F., Carré, N., Deveau, C. et al. HEMOCO: a French prospective study of hemophiliacs infected by human immunodeficiency virus type 1 (HIV-1). Hematol Cell Ther 38, 193–198 (1996). https://doi.org/10.1007/s00282-996-0193-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00282-996-0193-7